351
Participants
Start Date
January 5, 2024
Primary Completion Date
May 1, 2029
Study Completion Date
May 1, 2044
FT825
FT825 will be administered as an intravenous (IV) infusion at planned dose levels.
Fludarabine
Fludarabine will be administered as an IV infusion at planned dose levels.
Cyclophosphamide
Cyclophosphamide will be administered as an IV infusion at planned dose levels.
Bendamustine
Bendamustine will be administered as an IV infusion at planned dose levels.
Docetaxel
Docetaxel will be administered as an IV infusion at planned dose levels.
Cisplatin
Cisplatin will be administered as an IV infusion at planned dose levels.
Cetuximab
Cetuximab will be administered as an IV infusion at planned dose levels.
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RECRUITING
Sarah Cannon Research Institute (SCRI) - Oncology Partners, Nashville
RECRUITING
Ohio State University - Comprehensive Cancer Center, Columbus
RECRUITING
Oncology Hematology Care Clinial Trials, Cincinnati
RECRUITING
Karmanos Cancer Institute, Detroit
RECRUITING
University of Minnesota Medical School, Minneapolis
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
Washington University School of Medicine, St Louis
RECRUITING
OU Health Stephenson Cancer Center, Oklahoma City
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
University of California San Diego Moores Cancer Center, La Jolla
RECRUITING
Yale New Haven Hospital - Yale Cancer Center, New Haven
Lead Sponsor
Fate Therapeutics
INDUSTRY